1-(4-(4-phenylthiazol-2-ylamino)phenyl)ethanone | 708279-61-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-(4-phenylthiazol-2-ylamino)phenyl)ethanone
• 英文别名: 1-{4-[(4-Phenyl-1,3-thiazol-2-yl)amino]phenyl}ethanone；1-[4-[(4-phenyl-1,3-thiazol-2-yl)amino]phenyl]ethanone
• CAS: 708279-61-2
• 化学式: C₁₇H₁₄N₂OS
• 分子量: 294.377
• InChiKey: NGIWEDVRTXSWDF-UHFFFAOYSA-N

物化性质

• 沸点：
  495.4±47.0 °C(Predicted)
• 密度：
  1.252±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-(4-phenylthiazol-2-ylamino)phenyl)ethanone 、 盐酸氨基脲 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 10.0h， 以37%的产率得到2-(1-(4-((4-phenylthiazol-2-yl)amino)phenyl)ethylidene)hydrazinecarboxamide
  参考文献：
  名称：

  Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections

  摘要：

  The increasing emergence of antibiotic-resistant bacterial pathogens calls for additional urgency in the development of new antibacterial candidates. N-Phenyl-2-aminothiazoles are promising candidates that possess potent anti-MRSA activity and could potentially replenish the MRSA antibiotic pipeline. The initial screen of a series of compounds in this novel class against several bacterial strains revealed that the aminoguanidine analogues possessed promising activities and superior safety profiles. The determined MICs of these compounds were comparable to, if not better than, those of the control drugs (linezolid and vancomycin). Remarkably, compounds 3a, 3b, and 3e possessed potent activities against multidrug resistant staphylococcal isolates and several clinically important pathogens, such as vancomycin-resistant enterococci (VRE) and Streptococcus pneumoniae. In addition, the compounds were superior to vancomycin in the rapid killing of MRSA and the longer post-antibiotic effects. Furthermore, low concentrations of compounds 3a, 3b, and 3e reduced the intracellular burden of MRSA by greater than 90%. Initial in vitro PK/toxicity assessments revealed that compound 3e was highly tolerable and possessed a low metabolic clearance rate and a highly acceptable half-life. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112497
• 作为产物：
  描述：

  4-氨基苯乙酮 在 盐酸 、 sodium acetate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.0h， 生成 1-(4-(4-phenylthiazol-2-ylamino)phenyl)ethanone
  参考文献：
  名称：

  Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections

  摘要：

  The increasing emergence of antibiotic-resistant bacterial pathogens calls for additional urgency in the development of new antibacterial candidates. N-Phenyl-2-aminothiazoles are promising candidates that possess potent anti-MRSA activity and could potentially replenish the MRSA antibiotic pipeline. The initial screen of a series of compounds in this novel class against several bacterial strains revealed that the aminoguanidine analogues possessed promising activities and superior safety profiles. The determined MICs of these compounds were comparable to, if not better than, those of the control drugs (linezolid and vancomycin). Remarkably, compounds 3a, 3b, and 3e possessed potent activities against multidrug resistant staphylococcal isolates and several clinically important pathogens, such as vancomycin-resistant enterococci (VRE) and Streptococcus pneumoniae. In addition, the compounds were superior to vancomycin in the rapid killing of MRSA and the longer post-antibiotic effects. Furthermore, low concentrations of compounds 3a, 3b, and 3e reduced the intracellular burden of MRSA by greater than 90%. Initial in vitro PK/toxicity assessments revealed that compound 3e was highly tolerable and possessed a low metabolic clearance rate and a highly acceptable half-life. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112497

文献信息

• COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF
  申请人：Thiele Dennis J.

  公开号：US20110112073A1

  公开（公告）日：2011-05-12

  The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.

  本发明涉及HSF激活化合物，其发现方法，以及其研究和治疗用途，以及药学上可接受的盐类、溶剂化合物、螯合物、非共价络合物、前药、混合物（包括R和S对映体形式和它们的消旋混合物），以及其药物配方。具体而言，本发明提供了能够促进HSF1同聚三聚体化的化合物，以及使用这些化合物作为治疗剂治疗与异常HSF1活性相关的多种疾病的方法。
• SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS
  申请人：DUKE UNIVERSITY

  公开号：US20160221958A1

  公开（公告）日：2016-08-04

  The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.

  本发明涉及HSF激活化合物，其发现方法以及它们的研究和治疗用途，以及其药学上可接受的盐，溶剂化物，螯合物，非共价复合物，前药，混合物（包括R和S对映体形式和它们的混合物），以及其制剂。特别是，本发明提供了能够促进HSF1同源三聚体形成的化合物，以及使用这些化合物作为治疗剂治疗与不规则HSF1活性相关的多种疾病的方法。
• US9156775B2
  申请人：——

  公开号：US9156775B2

  公开（公告）日：2015-10-13
• US9315449B2
  申请人：——

  公开号：US9315449B2

  公开（公告）日：2016-04-19
• US9447058B2
  申请人：——

  公开号：US9447058B2

  公开（公告）日：2016-09-20